目的 研究美洛昔康咀嚼片在比格犬體內(nèi)的藥動(dòng)學(xué)和生物等效性。方法 12只健康成年比格犬隨機(jī)分為2組，采用雙周期交叉實(shí)驗(yàn)設(shè)計(jì)，分別口服測(cè)試片劑和參比片劑2 mg，用RP-HPLC方法測(cè)定血漿中美洛昔康的濃度，應(yīng)用3P97軟件計(jì)算藥動(dòng)學(xué)參數(shù)，并進(jìn)行兩種制劑的生物等效性評(píng)價(jià)。結(jié)果 測(cè)試片劑和參比片劑的AUC_{0~96 h}分別為（2.85±0.64）和（2.79±0.48）μg/mL·h，T_max分別為（4.33±0.65）和（4.16±0.71）h，C_max分別為（0.091±0.017）和（0.086±0.021）μg/mL，t_1/2分別為（26.08±3.64）和（26.94±4.21）h，兩者的lnAUC和lnC_max經(jīng)雙單側(cè)t檢驗(yàn)證明差異無(wú)統(tǒng)計(jì)意義。結(jié)論 測(cè)試片劑與國(guó)外上市的參比片劑具有生物等效性，其平均相對(duì)生物利用度為（98.0±9.76）%。

Objective To investigate in vivo pharmacokinetics and bioequivalence of Meloxicam Chewable Tablets in healthy Beagle's dogs. Method Twelve healthy adult Beagle's dogs were randomized into two groups. Using the double-preparation, double-cycle, cross-over method and administering orally of testing and reference tablet (2 mg) respectively. The plasma concentration of meloxicam was determinated by RP-HPLC. The 3P97 software was adopted to calculate the pharmacokinetic parameters and evaluate the bioequivalence of two preparations. Results The area under the curves (AUC_{0-96 h}) of the testing tablets and innovator tablets were (2.85±0.64) and (2.79±0.48) μg/mL·h. The peak time (T_max) was (4.33±0.65) and (4.16±0.71) h. The peak concentration (C_max) was (0.091±0.017) and (0.086±0.021) μg/mL. The half time (t_1/2) was (26.08±3.64) and (26.94±4.21) h. After the double unilateral t test, there was no statistical significance in the difference of lnAUC and lnC_max between the testing tablets and innovator tablets. Conclusion The testing tablets and innovator tablets are bioequivalent. The relative bioavailability of generic tablet is (98.0±9.76)%.